The development of novel allosteric ligands acting at the M1 muscarinic acetylcholine receptor

Selective activation of the M1 muscarinic acetylcholine receptor (M1 mAChR) may provide a useful approach for the treatment of the cognitive deficits associated with Alzheimer’s disease and schizophrenia.  Unfortunately, the development of subtype-selective drugs that target the orthosteric site (i.e., the acetylcholine binding site) of the M1 mAChR remains challenging because this site is highly conserved across the mAChR receptor family. Accordingly this project will focus on the development of positive allosteric modulators that target a less conserved and spatially distinct allosteric site.

The development of novel allosteric lingands acting at the M1 musicarinic acetylcholine receptor

Enhanced research experience

In one element of this program students will engage in the medicinal chemistry and the biological evaluation of the compounds. Students will develop skills in cell biology working in the labs of Prof. Michael Cowley, at Physiology at Monash or Dr. Nick Holiday at University of Nottingham.